All In MedTech

FDA Clearance Tracker · P190009-S007

OPRA™ Implant System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 15, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 15, 2025

Approved

Time to decision

89 days

Received Oct 18, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P190009-S007
Device name
OPRA™ Implant System
Applicant
Integrum AB
Applicant location
MöLndal
Received
Oct 18, 2024
Decided
Jan 15, 2025
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P190009

Device type

Device class
Class III

Every decision under product code PJY

FDA's approval statement

As written in FDA's record.

The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P190009

Source documents

Other decisions for Integrum AB

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.